세계의 감기약 및 독감 치료제 시장 규모 : 유형별, 용도별, 최종사용자별, 지역 범위별 및 예측

Global Cold And Flu Drugs Market Size By Type (Antihistamines, Decongestants), By Application (Prescription Medications, Over-the-Counter (OTC) Medications), By End User (Hospitals and Clinics, Retail Pharmacies), By Geographic Scope And Forecast

US $ 3,950 ￦ 5,419,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 보고서의 다운로드와 인쇄가 가능합니다.

US $ 4,850 ￦ 6,654,000

PDF & Excel (5 User License)

PDF 및 Excel 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 보고서의 다운로드와 인쇄가 가능합니다.

US $ 7,550 ￦ 10,359,000

PDF & Excel (Enterprise User License)

PDF 및 Excel 보고서를 동일기업내 모든 분들이 이용할 수 있는 라이선스입니다. 보고서의 다운로드와 인쇄가 가능합니다.

한글목차

감기약 및 독감 치료제 시장 규모 및 예측

감기약 및 독감 치료제 시장 규모는 2024년 168억 5,000만 달러로 평가되었고, 2026-2032년 연평균 7.20% 성장하여 2032년에는 293억 9,000만 달러에 달할 것으로 예측됩니다.

• 감기약이나 독감약은 주로 감기나 독감과 같은 바이러스성 질환의 증상을 치료하는 의약품입니다. 이러한 의약품에는 종종 일반의약품(OTC) 충혈제거제, 항히스타민제, 기침약, 아세트아미노펜이나 이부프로펜과 같은 진통제가 포함됩니다. 경우에 따라 심한 독감 증상을 치료하기 위해 복합 항바이러스제를 사용하기도 합니다. 이러한 치료는 감염을 치료하지는 않지만 발열, 기침, 인후통, 코막힘과 같은 증상을 완화하고 환자에게 안도감을 주며 질병 기간 동안 삶의 질을 향상시킬 수 있습니다.
• 바이러스성 호흡기 질환의 유병률 상승과 세계 인구 증가에 따라 감기약 및 독감약의 개발은 순조롭게 진행될 것으로 예측됩니다. 여러 질환을 치료하는 병용요법 등 약물의 배합이 발전함에 따라 환자의 편의성과 효과가 향상될 것으로 예측됩니다.
• 새로운 항바이러스제 및 시중에서 유행하는 독감 균주와 싸우기 위한 예방접종 개발은 시장 성장을 가속할 것으로 예측됩니다. 계절성 독감 예방 및 건강 관리에 대한 지식이 증가함에 따라, 특히 대유행 시에는 일반의약품 및 처방전 없이 구입할 수 있는 감기약에 대한 수요가 증가할 것으로 예측됩니다. 원격 의료와 인터넷 약국의 출현으로 이러한 약품의 전 세계 가용성과 소비가 증가할 것입니다.

감기약 및 독감약 세계 시장 역학

세계 감기약 및 독감 치료제 시장을 형성하는 주요 시장 역학은 다음과 같습니다.

주요 시장 성장 촉진요인

• 독감 및 감기 발병률 증가: 독감 및 감기 발병률 증가: 전 세계적으로 독감 및 감기 발병률이 높아지면서 감기약 및 독감 치료제 수요를 견인하고 있습니다. 세계보건기구(WHO)에 따르면, 매년 독감 유행으로 인해 전 세계적으로 약 300만-500만 명의 중증 환자가 발생하고 있습니다. 미국 질병통제예방센터(CDC)는 2010-2020년 사이 독감으로 인해 연간 900만 명에서 4,100만 명이 사망한 것으로 추정하고 있습니다.
• 고령화 인구 증가: 노인은 면역력이 저하되어 감기나 독감에 쉽게 감염될 수 있습니다. 유엔 경제사회국에 따르면 전 세계 65세 이상 인구는 2050년까지 15억 명에 달하고, 2020년 7억 2,700만 명에서 거의 두 배로 늘어날 것으로 예측됩니다. 이러한 인구 통계학적 변화로 인해 감기약 및 독감약에 대한 수요가 증가할 가능성이 높습니다.
• 의료비 지출 증가: 특히 신흥국의 의료비 지출 증가는 감기약 및 독감약 시장의 성장을 가속하고 있습니다. 세계은행 데이터에 따르면 GDP 대비 세계 의료비 비중은 2000년 8.5%에서 2018년 9.8%로 상승했습니다. 미국 메디케어 메디케이드 서비스 센터(CMS)의 보고에 따르면 국민 의료비는 9.7% 성장하여 2020년에는 4.1조 달러로 GDP의 19.7%를 차지할 것으로 예측됩니다.

주요 과제

• 항바이러스제 내성 증가: 독감 바이러스의 항바이러스제 내성 균주의 출현은 감기약과 독감 치료제 시장에 큰 도전이 되고 있습니다. 바이러스가 변이를 일으키면 오셀타미비르(타미플루)와 같은 기존 항바이러스 치료제에 반응하지 않을 수 있습니다. 이러한 내성은 약물의 효능을 떨어뜨리고 질병의 장기화와 감염률 증가로 이어질 수 있습니다. 제약회사는 새로운 항바이러스제 발견을 위한 연구개발(R&D)에 지속적으로 투자해야 하는데, 이는 시간과 비용이 많이 소요됩니다. 바이러스의 변이에 대응하는 최신 치료제가 필요하기 때문에 의료 자원이 부족하여 치료 지연으로 이어질 수 있습니다.
• 의약품 승인을 위한 규제적 장애물: 새로운 감기약이나 독감 치료제를 승인받기 위해서는 FDA나 EMA와 같은 기관의 엄격한 규제 요건으로 인해 길고 복잡한 과정을 거쳐야 합니다. 이러한 규제는 의약품의 안전성과 유효성을 보장하기 위한 것이지만, 혁신적인 치료법의 도입을 지연시킬 수 있습니다. 임상시험에서 약물이 증상을 완화시킬 뿐만 아니라 부작용이 최소화된다는 것을 증명해야 합니다. 이러한 규제 상황에 대응하는 것은 시장 출시에 소요되는 비용과 시간을 증가시키고, 바이러스 균주의 출현과 환자 니즈의 변화에 신속하게 대응하는 기업의 능력을 제한할 수 있습니다.
• 부작용 및 안전성 우려: 많은 감기약 및 독감약, 특히 일반의약품은 졸음, 어지럼증, 알레르기 반응 등의 부작용을 동반합니다. 충혈제거제나 항히스타민제 등 성분에 따라서는 고혈압, 심장병 등 지병이 있는 환자에게 합병증을 유발할 수 있습니다. 이러한 안전성에 대한 우려로 인해 소비자들은 특정 제품을 피하거나 대체 치료법을 찾게 되고, 이는 시장 수요에 영향을 미칠 수 있습니다.

주요 동향

• 호흡기 감염증의 유병률 증가: 감기, 독감 등 호흡기 감염증의 유병률 증가는 감기약 및 독감 치료제 시장의 주요 촉진요인 중 하나입니다. 기후 변화, 도시화, 고령화로 인해 바이러스 감염에 걸리기 쉬운 환경이 조성되고 있습니다. 전 세계적으로 오염 수준이 높아지면 호흡기 건강을 약화시키고 개인을 감염에 취약하게 만듭니다. 특히 계절성 독감 유행이나 코로나19와 같은 전염병이 유행할 때, 소비자는 생산성을 유지하기 위해 즉각적인 증상 완화를 원하기 때문에 이러한 지속적인 추세는 일반의약품과 항바이러스제에 대한 수요를 증가시키고 있습니다.
• 일반의약품(OTC)에 대한 선호도 증가: 셀프 메디케이션(self-medication)으로의 전환이 가속화되고 있으며, 점점 더 많은 소비자들이 OTC 감기약과 독감 치료제를 선택하고 있습니다. 이러한 추세의 배경에는 접근성, 저렴한 가격, 의료 전문가를 방문하지 않고도 증상을 치료하고자 하는 욕구 등이 있습니다. 많은 OTC 의약품은 하나의 제품으로 여러 증상에 대응할 수 있는 복합 치료를 제공합니다. 처방전 없이 약국이나 온라인 플랫폼에서 이러한 의약품을 구매할 수 있는 편리함이 수요 증가에 크게 기여하고 있습니다.
• 병용요법에 대한 수요: 코막힘, 기침, 두통 등 여러 증상을 한 번에 해결할 수 있는 병용요법을 찾는 소비자들이 늘고 있습니다. 이러한 추세를 주도하는 것은 편의성이며, 환자들은 여러 가지 증상에 대해 여러 가지 약을 복용하는 것보다 올인원 솔루션을 선호하고 있습니다. 제약회사들은 일반적인 감기나 독감 증상을 완화하는 다증상 치료제를 개발하여 이에 대응하고 있습니다. 여러 증상을 동시에 관리할 수 있는 이러한 치료법은 바쁜 라이프스타일을 가진 개인에게 매력적이며, 감기약 및 독감 치료제 시장의 중요한 촉진제 역할을 하고 있습니다.

목차

제1장 세계의 감기약 및 독감 치료제 시장 서론

• 시장 개요
• 조사 범위
• 전제조건

제2장 주요 요약

제3장 VERIFIED MARKET RESEARCH의 조사 방법

• 데이터 마이닝
• 밸리데이션
• 1차 자료
• 데이터 소스 리스트

제4장 세계의 감기약 및 독감 치료제 시장 전망

• 개요
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
• Porter's Five Forces 모델
• 밸류체인 분석

제5장 세계의 감기약 및 독감 치료제 시장 : 유형별

• 개요
• 항히스타민제
• 울혈 제거제

제6장 세계의 감기약 및 독감 치료제 시장 : 용도별

• 개요
• 처방약
• 시판약

제7장 감기약 및 독감 치료제 시장 : 최종사용자별

• 병원 클리닉
• 소매 약국

제8장 세계의 감기약 및 독감 치료제 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 기타 유럽
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 기타 아시아태평양
• 라틴아메리카
  • 브라질
  • 아르헨티나
  • 기타 라틴아메리카
• 중동 및 아프리카
  • 아랍에미리트(UAE)
  • 사우디아라비아
  • 남아프리카공화국
  • 기타 중동 및 아프리카

제9장 세계의 감기약 및 독감 치료제 시장 경쟁 구도

• 개요
• 기업의 시장 순위
• 주요 개발 전략

제10장 기업 개요

• Johnson & Johnson
• GlaxoSmithKline, Pfizer
• Novartis
• Sanofi
• AstraZeneca
• Bayer
• Reckitt Benckiser
• Procter & Gamble
• Mylan
• Pfizer

제11장 부록

• 관련 조사

LSH

영문 목차

영문목차

Cold And Flu Drugs Market Size And Forecast

Cold And Flu Drugs Market size was valued at USD 16.85 Billion in 2024 and is projected to reach USD 29.39 Billion by 2032, growing at a CAGR of 7.20% from 2026 to 2032.

• Cold and flu drugs are medical products that treat the symptoms of viral diseases, primarily the common cold and influenza. These medications often include over-the-counter (OTC) decongestants, antihistamines, cough suppressants, and pain relievers such as acetaminophen or ibuprofen. In some situations, prescription antiviral drugs are utilized to treat severe flu symptoms. While these treatments do not cure infections, they do alleviate symptoms such as fever, cough, sore throat, and nasal congestion, giving patients relief and enhancing their quality of life during the illness.
• The market for cold and flu medications is expected to develop steadily as the prevalence of viral respiratory diseases rises and the worldwide population grows. Advances in medicine formulations, such as combination therapies that treat several ailments, are predicted to improve patient convenience and effectiveness.
• The development of novel antiviral medicines and vaccinations to combat developing flu strains will aid market growth. With increased knowledge of seasonal flu prevention and health management, particularly during the pandemic, demand for both over-the-counter and prescription cold and flu treatments is expected to stay high. The advent of telemedicine and internet pharmacies will increase the global availability and consumption of these drugs.

Global Cold And Flu Drugs Market Dynamics

The key market dynamics that are shaping the global cold and flu drugs market include:

Key Market Drivers:

• Increasing Incidence of Influenza and Common Cold: The high prevalence of influenza and common cold cases globally drives the demand for cold and flu medications. According to the World Health Organization (WHO), annual influenza epidemics result in about 3 to 5 million cases of severe illness worldwide. In the United States alone, the Centers for Disease Control and Prevention (CDC) estimates that influenza has resulted in 9 million to 41 million illnesses annually between 2010 and 2020.
• Growing Aging Population: The elderly population is more susceptible to cold and flu infections due to weakened immune systems. The United Nations Department of Economic and Social Affairs reports that the global population aged 65 and above is expected to reach 1.5 billion by 2050, nearly doubling from 727 million in 2020. This demographic shift is likely to increase the demand for cold and flu medications.
• Rising Healthcare Expenditure: Increased healthcare spending, particularly in developing countries, is driving the growth of the cold and flu drugs market. The World Bank data shows that global health expenditure as a percentage of GDP has risen from 8.5% in 2000 to 9.8% in 2018. In the United States, the Centers for Medicare & Medicaid Services (CMS) reported that national health spending grew 9.7% to reach $4.1 trillion in 2020, accounting for 19.7% of GDP.

Key Challenges:

• Growing Resistance to Antiviral Medications: The emergence of antiviral-resistant strains of flu viruses presents a significant challenge in the cold and flu drugs market. As viruses mutate, they can become less responsive to existing antiviral treatments, such as oseltamivir (Tamiflu). This resistance diminishes the effectiveness of these drugs, leading to prolonged illness and increased transmission rates. Pharmaceutical companies must continuously invest in research and development (R&D) to discover new antiviral agents, which can be time-consuming and costly. The need for updated treatments in response to viral mutations can strain healthcare resources and lead to treatment delays.
• Regulatory Hurdles for Drug Approval: Gaining approval for new cold and flu drugs can be a lengthy and complex process due to stringent regulatory requirements from bodies like the FDA and EMA. These regulations aim to ensure the safety and efficacy of medications but can delay the introduction of innovative treatments. Clinical trials must demonstrate not only that the drugs alleviate symptoms but also that they have minimal side effects. Navigating this regulatory landscape can increase the cost and time to market, limiting the ability of companies to swiftly respond to emerging viral strains or changing patient needs.
• Side Effects and Safety Concerns: Many cold and flu medications, especially OTC options, are associated with side effects like drowsiness, dizziness, or allergic reactions. Certain ingredients, such as decongestants or antihistamines, can cause complications in patients with pre-existing conditions like hypertension or heart disease. These safety concerns may lead consumers to avoid certain products or seek alternative treatments, thereby affecting market demand.

Key Trends:

• Rising Prevalence of Respiratory Infections: The increasing incidence of respiratory infections, such as colds and the flu, is one of the primary drivers of the cold and flu drugs market. Changes in climate, growing urbanization, and an aging population contribute to higher susceptibility to viral infections. The global rise in pollution levels weakens respiratory health, making individuals more prone to infections. This ongoing trend increases the demand for over-the-counter medications and antiviral drugs, as consumers seek immediate relief from symptoms to maintain productivity, particularly during seasonal flu outbreaks and pandemics like COVID-19.
• Growing Preference for Over-the-counter (OTC) Drugs: There is a growing shift toward self-medication, with consumers increasingly opting for OTC cold and flu drugs. This trend is driven by factors like easy accessibility, affordability, and the desire to manage symptoms without visiting healthcare professionals. Many OTC medications offer combination treatments, addressing multiple symptoms in a single product. The convenience of purchasing these drugs at pharmacies or online platforms without a prescription has contributed significantly to their rising demand
• Demand for Combination Therapies: Consumers are increasingly seeking combination therapies that address multiple symptoms such as congestion, cough, and headaches in a single dose. This trend is driven by the convenience factor, as patients prefer all-in-one solutions rather than taking multiple drugs for different symptoms. Pharmaceutical companies have responded by developing multi-symptom medications that offer relief for common cold and flu symptoms. The efficiency of these treatments in managing several symptoms simultaneously appeals to individuals with busy lifestyles, making them a significant driver of the cold and flu drugs market.

Global Cold And Flu Drugs Market Regional Analysis

Here is a more detailed regional analysis of the global cold and flu drugs market:

North America:

• North America's dominance in the cold and flu drugs market, including the high incidence of respiratory illnesses and an advanced healthcare infrastructure. The United States alone experiences millions of flu cases annually, with the CDC reporting an average of 9 million to 45 million influenza cases each year. This, combined with widespread access to healthcare and over-the-counter (OTC) medications, creates a robust demand for cold and flu treatments.
• The aging population in North America, which is more vulnerable to respiratory infections, fuels the need for effective and accessible cold and flu drugs. Increased awareness around self-medication for minor ailments and the availability of OTC products further support the market's growth.
• The cold and flu drugs market is projected to grow at a compound annual growth rate (CAGR) of 5.8% from 2023 to 2028. Heightened awareness due to the COVID-19 pandemic has led to a surge in demand for respiratory illness treatments, further boosting the market. Significant investments in research and development, like the NIH's allocation of $484 million for influenza research in 2023, underline the region's commitment to advancing respiratory treatments.

Asia Pacific:

• The cold and flu drugs market in the Asia Pacific region is experiencing rapid growth. The region's large and expanding population, which accounts for about 60% of the global population, plays a central role in the market's expansion. Rising urbanization and increased pollution levels contribute to a higher incidence of respiratory illnesses, fueling the demand for cold and flu medications. The growing middle class and rising disposable incomes across the region enable more people to invest in healthcare products, including over-the-counter (OTC) medications. Southeast Asia, in particular, has seen annual healthcare expenditure growth rates between 6-12%, highlighting a significant increase in healthcare access and spending.
• Another critical driver is the region's aging population, particularly in East Asia and the Pacific, where the percentage of people aged 60 and above is expected to rise from 13.8% in 2020 to 27.6% by 2050. Older adults are more vulnerable to respiratory infections, increasing the demand for cold and flu drugs. The region's expanding healthcare infrastructure, government initiatives to improve healthcare access, and the rise of e-commerce platforms have made cold and flu medications more accessible.

Global Cold And Flu Drugs Market: Segmentation Analysis

The Global Cold And Flu Drugs Market is Segmented on the basis of Type, Application, End User, And Geography.

Cold And Flu Drugs Market, By Type

• Antihistamines
• Decongestants

Based on Type, the market is fragmented into Antihistamines and decongestants. Antihistamines dominate due to their widespread use in managing symptoms such as sneezing, runny nose, and watery eyes, which are common in colds and flu. They are a key component in many over-the-counter cold remedies and are favored for their ability to provide quick relief from allergy-like symptoms associated with viral infections. Decongestants are a rapidly growing segment, driven by the rising demand for medications that relieve nasal congestion and sinus pressure, particularly during flu seasons. Decongestants are often sought after for their effectiveness in reducing inflammation and easing breathing, making them essential in cold and flu treatment.

Cold And Flu Drugs Market, By Application

• Prescription Medications
• Over-the-Counter (OTC) Medications

Based on Application, the market is divided into Prescription Medications and over-the-counter (OTC) Medications. Over-the-counter (OTC) Medications dominate due to their ease of accessibility and wide availability without the need for a doctor's prescription. Consumers prefer OTC medications for immediate relief from common cold and flu symptoms, making them the go-to choice during seasonal outbreaks. This segment is driven by consumer awareness and the convenience of purchasing from pharmacies, supermarkets, and online platforms. Prescription Medications are rapidly growing, particularly for severe or persistent cases that require more specialized treatments.

Cold And Flu Drugs Market, By End User

• Hospitals and Clinics
• Retail Pharmacies

Based on End User, the market is segmented into Hospitals and Clinics, and Retail Pharmacies. Retail Pharmacies dominate due to their accessibility and convenience for consumers seeking over-the-counter medications. Retail pharmacies are widely available, making them the first point of contact for people looking for quick relief from cold and flu symptoms. The rise of online pharmacies has further fueled this segment's growth. Hospitals and Clinics represent a rapidly growing segment, particularly for more severe cases requiring prescription medications or treatment for complications. Increased healthcare visits during flu seasons and the growing preference for professional consultations in complex cases are driving the demand in this segment.

Cold And Flu Drugs Market, By Geography

• North America
• Asia Pacific
• Europe
• Rest of the world
• On the basis of geographical analysis, the Global Cold And Flu Drugs Market is classified into North America, Asia Pacific, Europe, and Rest of the world. North America stands out as a dominant region due to its advanced healthcare system, high awareness of cold and flu treatments, and strong consumer demand for over-the-counter drugs. Asia Pacific is experiencing rapid growth, driven by increasing healthcare access, rising disposable incomes, and a growing population.

Key Players

The "Global Cold And Flu Drugs Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Johnson & Johnson, GlaxoSmithKline, Pfizer, Novartis, Sanofi, AstraZeneca, Bayer, Reckitt Benckiser, Procter & Gamble, and Mylan. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Cold And Flu Drugs Market Recent Developments
• In September 2023, BMS disclosed that as part of a strategic license and partnership to create and market obexelimab, a brand-new, bi-functional antibody for autoimmune disorders, it will pay Zenas BioPharma $50 million upfront.
• In May 2022, Nature's Way Products, LLC, announced a significant expansion of its Green Bay, Wisconsin, Gummy factory. Incorporating production, packaging, and warehouse space, the development will increase the present 80,000 square feet by 116,000 square feet. Early summer was the planned start date, and the project should be finished by the end of the third quarter of 2023.

TABLE OF CONTENTS

1 INTRODUCTION OF THE GLOBAL COLD AND FLU DRUGS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL COLD AND FLU DRUGS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porter's Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL COLD AND FLU DRUGS MARKET, BY TYPE

• 5.1 Overview
• 5.2 Antihistamines
• 5.3 Decongestants

6 GLOBAL COLD AND FLU DRUGS MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Prescription Medications
• 6.3 Over-the-Counter (OTC) Medications

7 COLD AND FLU DRUGS MARKET, BY END USER

• 7.1 Hospitals and Clinics
• 7.2 Retail Pharmacies

8 GLOBAL COLD AND FLU DRUGS MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 The U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 The U.K.
  • 8.3.3 France
  • 8.3.4 Italy
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Argentina
  • 7.5.3 Rest of LATAM
• 8.6 Middle East and Africa
  • 8.6.1 UAE
  • 8.6.2 Saudi Arabia
  • 8.6.3 South Africa
  • 8.6.4 Rest of the Middle East and Africa

9 GLOBAL COLD AND FLU DRUGS MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Johnson & Johnson
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 GlaxoSmithKline, Pfizer
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Novartis
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Sanofi
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 AstraZeneca
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Bayer
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Development
• 10.7 Reckitt Benckiser
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Procter & Gamble
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Development
• 10.9 Mylan
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Development
• 10.10 Pfizer
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Development

11 Appendix

• 11.1 Related Research

관련자료